Roxadustat not checked

Kyntra Bio · FG-4592 · ASP1517

FollowEvery change as it happens, and a Monday email
Next date
Phase 3 trial completes
Trials
2 active
18 in total · 1 in the EU
Targets
 

What this is

How it works
How it works isn't classified yet
How it’s given
“Roxadustat will be administered per schedule specified in the arm description.”In the company’s words, NCT07722988 on ClinicalTrials.gov
Tested for
Myelodysplastic Syndromes
Main trialPhase 3
“The study is designed to determine the efficacy and safety of roxadustat for the treatment of anemia due to very low, low, or intermediate risk MDS in participants with high transfusion burden (HTB).”In the company’s words, NCT07722988 on ClinicalTrials.gov
Other names
FG-4592 · ASP1517 · AZD9941

Other drugs for Myelodysplastic Syndromes

All 96 drugs for Myelodysplastic Syndromes

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials18

TrialPhaseCompletesWhat it tests
Phase 3Not yet recruiting Sep 2030 A Study to Investigate the Efficacy and Safety of Roxadustat (FG-4592) for Treating Anemia in Participants With Myelodysplastic Syndromes (MDS)
Phase 4Completed 19 Nov 2021 Evaluate the Efficacy and Safety of Multiple Roxadustat Dosing Regimens for the Treatment of Anemia in Dialysis Participants With Chronic Kidney Disease
Phase 3Completed 19 Sep 2018 Study to Evaluate the Efficacy and Safety of Roxadustat in the Treatment of Anemia in Participants With ESRD on Stable Dialysis
Phase 3Completed 21 Sep 2018 Safety and Efficacy Study of Roxadustat (FG-4592) for the Treatment of Anemia in End-Stage Renal Disease (ESRD) Newly Initiated Dialysis Participants
Phase 3Completed 24 Sep 2018 A Study of Roxadustat for the Treatment of Anemia in Participants With Chronic Kidney Disease and Not Receiving Dialysis
Phase 3Completed 30 Jun 2021 Study of Roxadustat Conversion in Participants Receiving Stable Erythropoiesis-Stimulating Agent (ESA) or as Initial Anemia Treatment in Chronic Dialysis Participants
Phase 3Completed 9 Jul 2021 Study of Roxadustat Conversion in Participants Receiving Stable ESA or as Initial Anemia Treatment in Hemodialysis Participants
Phase 3Withdrawn 23 May 2022 Investigating the Efficacy, Safety and PK of Roxadustat (FG-4592) for Treatment of Anemia in Pediatric Patients With CKD
Phase 3Terminated 9 Mar 2023 Efficacy and Safety of Roxadustat for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome With Low Red Blood Cell Transfusion Burden
Phase 3Completed 3 Apr 2023 A Study to Evaluate the Efficacy and Safety of Roxadustat for the Treatment of Anemia in Participants Receiving Chemotherapy Treatment for Non-Myeloid Malignancies
Phase 2/3Completed 11 Jan 2023 Efficacy and Safety of FG-4592 for Treatment of Anemia in Participants With Lower Risk Myelodysplastic Syndrome (MDS)
Phase 2Completed 21 Jun 2010 Phase 2 Study of Roxadustat in Participants With Anemia and Chronic Kidney Disease Not Requiring Dialysis
Phase 2Completed 13 Jun 2012 Study of Roxadustat in Non-Dialysis Chronic Kidney Disease Participants With Anemia
Phase 2Completed 15 Oct 2012 Study of Roxadustat (FG-4592) in Participants With End-Stage Renal Disease Receiving Maintenance Hemodialysis
Phase 2Completed 10 Jan 2013 Study of Roxadustat (FG-4592) to Correct Anemia in Newly Initiated Dialysis Participants Not on Erythropoiesis-Stimulating Agent Treatment
Phase 2Completed 12 Dec 2019 Open-Label Extension Study for the Long-Term Efficacy and Safety of Roxadustat in Participants With Dialysis and Non-Dialysis Chronic Kidney Disease
Phase 2Completed 26 Mar 2021 Evaluation of Efficacy and Safety of Roxadustat for the Treatment of Chemotherapy Induced Anemia
Phase 4Authorised not given Effect of Roxadustat on Cardiometabolism
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 19 Nov 2026 · EU trials register (CTIS) updated 19 Nov 2026 · openFDA updated 19 Nov 2026

Follow Roxadustat

Following is part of Solo: you see every change to Roxadustat the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in